ANTIVIRAL ACTIVITY OF COMPOUNDS CONTAINING A STRUCTURAL FRAGMENT OF BENZOPYRAN-2-ONE

DOI: https://doi.org/10.29296/25877313-2022-06-03
Issue: 
6
Year: 
2022

D.S. Zolotyh
Ph.D. (Pharm.) Associate Professor, Analytical Chemistry Department,
Pyatigorsk Medical and Pharmaceutical Institute (Pyatigorsk, Russia)
E-mail: metranidazol@mail.ru
Z.V. Dayronas
Dr.Sc. (Pharm.), Professor, Department of Pharmacognosy, Botany and Technology of Phytopreparations,
Pyatigorsk medical and pharmaceutical institute (Pyatigorsk, Russia)
E-mail: daironas@mail.ru
D.I. Pozdnyakov
Ph.D. (Pharm.), Head of Living System Laboratory,
Associate Professor of Department of Pharmacology with Clinical Pharmacology Course,
Pyatigorsk Medical and Pharmaceutical Institute (Pyatigorsk, Russia)

Benzopyran-2-oh derivatives are characterized by an extensive spectrum of pharmacological activity, among which antiviral properties are particularly distinguished. It is worth noting that both natural derivatives of benzopyran-2-one and their semi-synthetic analogues have antiviral activity. It is par-ticularly relevant to evaluate the effectiveness of benzopyran-2-one derivatives in relation to the SARS-CoV-2 virus. A number of studies indicate that benzopyran-2-ones are able to suppress the main virulence factors of SARS-CoV-2: the receptor-binding domain of the S-protein, the main and papain-like proteases. As SARS-CoV-2 inhibiting agents, hebulinic acid and punicalagin are of the greatest interest, which combine a polyvalent mechanism of antiviral action, high efficiency and low toxicity.

Keywords: 
antiviral properties
benzopyran-2-one derivatives
SARS-CoV-2.

References: 
  1. Hyaying Fan, Zhenfang Gao, Kai Ji et al. The in vitro and in vivo anti-inflammatory effect of osthole, the major natural
  2. coumarin from Cnidium monnieri (L.) Cuss, via the blocking of the activationof the NF-κB and MAPK/p38 pathways. Phytomedicine. 2019; 58: 152864
  3. Toshihiro Aoki, Ikumi Hyohdoh, Noriyuki Furuichi et al. Optimiz-ing the Physicochemical Properties of Raf/MEK Inhibitors by Ni-trogen Scanning. ACS Med. Chem. Lett. 2014; 5(4): 304309.
  4. Lan Xie, Donglei Yu, Carl Wild et al. Anti-AIDS Agents. 52. Syn-thesis and Anti-HIV Activity of Hydroxy-methyl(3′R,4′R)-3′,4′-Di-O-(S)-camphanoyl-(+)-cis-khellac-tone Derivatives. J. Med. Chem. 2004; 47: 756760.
  5. Jian Tang, Keduo Qianb, Bei-Na Zhang, et. al. Anti-AIDS agents 82: Synthesis of seco-(3’R,4’R)-3’,4’-di-O-(S)-cam-phanoyl-(+)-cis-khellactone (DCK)derivatives as novel anti-HIV agents. Bioor-ganic & Medicinal Chemistry. 2010; 18: 4363–4373
  6. Xuemei Yu, Sainz Bruno (Jr.), Petukhov Р.A., et al. Identification of Hepatitis C Virus Inhibitors Targeting Different Aspects of Infec-tion Using a Cell-Based Assay. Antimicrobial Agents and Chemo-therapy. 2012; 56(12): 61096120.
  7. Jih Ru Hwu, Shu-Yu Lin, Shwu-Chen Tsay, et al. Coumarin-Purine Ribofuranoside Conjugates as New Agents against Hepatitis C Vi-rus. J. Med. Chem. 2011; 54: 2114–2126.
  8. Kudo E., Taura M., Matsuda K., et al. Inhibition of HIV-1 replica-tion by a tricyclic coumarin GUT-70in acutely and chronically in-fected cells. Bioorganic & Medicinal Chemistry Letters. 2013; 23: 606609.
  9. V’kovski Ph., Kratzel A., Steiner S., et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews Mictrobiology. 2021; 19: 155170.
  10. Arya R., Kumari S., Pandey B., et al. Structural insights into SARS-CoV-2 proteins. Journal of Molecular Biology. 2021; 433: 166725.
  11. Banerjee R., Perera L., Tillekeratne L.M.V. Potential SARS-CoV-2 main protease inhibitors. Drug Discov Today. 2021; 26(3): 804816.
  12. Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug tar-get. Bioorg. Med. Chem. Lett. 2020; 1 (30(17)): 127377.
  13. Du R., Cooper L., Chen Z., et al. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. Antiviral Res. 2021; 190: 105075.
  14. Malla Tika R., Tumber A., John T., et al. Mass spectrometry re-veals potential of β-lactamsas SARS-CoV-2 Mpro inhibitors. Chem. Commun. 2021; 57: 1430.
  15. Loschwitz J., Jackering A., Keutmann M., et al. Novel in-hibitors of the main protease enzyme of SARS-CoV-2 iden-tified viamolecular dynamics simulation-guided in vitro assay. Bioorganic Chemistry. 2021; 11: 104862.
  16. Milligan J.C., Zeisner T.U., Papageorgiou G., et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease. Biochem. J. 2021; 16; 478(13): 24992515.
  17. Hartenian E., Nandakumar D., Lari A. The molecular virology of coronaviruses. J. Biol. Chem. 2020; 11; 295(37): 1291012934.
  18. Suručić R., Travar M., Petković M., et al. Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-gly-coprotein binding ability to ACE2 Receptor: In silico and in vitro studies. Bioorg. Chem. 2021; 114: 105145.
  19. Mouffouk C., Mouffouk S., Mouffouk S., et al. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). Eur. J. Pharmacol. 2021; 15, 891: 173759.
  20. Chaudhuri Ratan K. Methods and composition for mitigating symptoms of acute respiratory distress syndrome. U.S. Patent № US 2021/0236580 A1. 2021.
  21. Bestle D., Heindl M.R., Limburg H. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human air-way cells. Life Sci Alliance. 2020; 23 (3(9)): e202000786
  22. Kiba Y., Oyama R., Misawa S., et al. Screening for inhibitory ef-fects of crude drugs on furin-like enzymatic activities. J. Nat. Med. 2021; 75(4): 10801085.
  23. Gribbon P., Zaliani A., Ellinger B., et al. Composition for corona-virus infection treatment and/or prevention. World Intellectual Prop-erty Organization Patent № WO 2021/198440 A1. 2021.